Prevention trial for heart outcomes in people with type 2 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have type 2 diabetes for at least 6 months
- Be age 40 or older
- Do not have known serious heart or stroke history
- Blood tests suggest higher heart strain (NT-proBNP above 125 pg/mL)
- Kidney function is adequate (eGFR 45 or higher)
- Blood pressure and heart rate at the start are not too low (SBP at least 100 and HR at least 60)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain diabetes medicines, called SGLT2 inhibitors and GLP-1 receptor agonists, can help protect the heart in people with type 2 diabetes. It may help you understand if these treatments are a good option for your heart health.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This trial tests a screening and intervention approach for “silent” coronary artery disease (heart artery narrowing without major symptoms) in people with type 2 diabetes. It may help prevent future heart problems by finding higher-risk cases early and starting the right treatment plan.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
This trial tests a heart-focused prevention approach to lower the risk of cardiac (heart) events in adults with type 2 diabetes. It may help by targeting early stress on the heart measured with a specific blood test.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.